The next big thing will likely be clinical trials and the ability to gain access to more favorable methods of funding for trials as well as general expenses. Companies such as Inergetics that are more diversified in their product lineups will have even easier time finding better financing options.

I would also expect many of the current successful MJ related companies, both private and publicly owned, to become juicy targets for much bigger companies that are seeking better margins.